Paris, 9^th October 2023

VISIOMED GROUP (FR0013481835 - ALVMG), a group dedicated to innovative healthcare technologies and services, submitted to Euronext and releases to the public its half-year financial report for the January, 1^st 2023 to June, 30^th 2023 period.

In line with its strategic plan, Visiomed Group confirms its strong trajectory during the first half of 2023:

• Significant growth in Medical Fitness revenue
• Strong improvement of its EBITDA
• Strong improvement of its net income
• Positive operating cash flow

Smart Salem's great momentum, with a number of medical tests increasing by 34%, has boosted group revenue for the first half of 2023 which reached €6.4m (a 41% growth compared to the first half of 2022 on a like-for-like basis).

For more than a year, Visiomed Group's strategy to focus on profitable growth, coupled with a sharp reduction in operating costs along with a clear repositioning of its operations, have enabled the company to report a consolidated positive EBITDA of €0.9m for the first half of 2023 (i.e. a margin of 14.2%) compared to an EBITDA loss of €(0.5)m for the same period in 2022.

Group's consolidated net profit also showed a strong growth of +€1.8m versus the first half of 2022.

The Group's operating cash flow from operations was also positive (+€0.8m), and consolidated net debt was €5.9m as of 30 June 2023.

Outlook for the second half of the year

The Group's outlook for the end of the financial year is positive, with a significant acceleration in Smart Salem's activity expected in the 3^rd quarter of 2023, reflecting the ramp-up of our last two centres and the success of the diversification of our offering.

A press release on Q3 activity will be published on October, 11^th 2023 after close of trading.

About VISIOMED GROUP

Founded in 2007, VISIOMED GROUP relies on a long experience in the health sector to invest in innovative health technologies and services in France and abroad.

The Group now has focused its activities on the Middle East since 2021 and the acquisition of Smart Salem, the first digital medical analysis centre accredited by the Dubai Health Authority (DHA) in the United Arab Emirates, 100% owned by Visiomed Group.

Visiomed is also accelerating its development in the region with the creation of Smart Health, a joint venture that will lead the deployment of the Group's innovative centres in Saudi Arabia.

Based in Paris, Visiomed Group is listed on Euronext Growth (ALVMG). For more information, visit www.visiomed-group.com

CONTACTS

© Visiomed Group SA 2023. The brands mentioned are the property of their respective authors. Reproduction prohibited, even partial, without prior authorization.